| Description |
Pulmonary hypertension refers to a group of diseases in which the pressure of the pulmonary artery is progressively increased due to various reasons, which can lead to right heart failure or even death. Pulmonary hypertension, a type of pulmonary hypertension which cause is unknown is called idiopathic pulmonary hypertension, excluding other primary diseases such as congenital heart disease, connective tissue disease, pulmonary embolism, etc. The treatment of idiopathic pulmonary hypertension is limited, which can only be partially relieved and cannot be cured. In recent clinical trail, transplanting normal human peripheral blood stem cells into patients with pulmonary hypertension can improve the symptoms of patients. In animal experiments, transplanting bone marrow CD34+ cells from pulmonary hypertension model mice into normal mice can cause the pulmonary artery pressure of normal mice to increase. This suggests that hematopoietic stem cells in peripheral blood may be related to the occurrence and development of pulmonary hypertension. The damage and repair of endothelial cells is a dynamic process, and this dynamic imbalance is considered to be the main cause of pulmonary hypertension. The damage of the endothelium leads to the release of inflammatory factors, the adhesion of immune cells, the proliferation of the smooth base layer, the contraction of blood vessels and the remodeling of the vessel wall. The metabolism and repair of the pulmonary artery wall is mediated by endothelial progenitor cells (EPCs) in the blood. Endothelial progenitor cells are differentiated from peripheral blood stem cells. The purpose of our research is: To compare the differentiation of hematopoietic stem cells between patients with pulmonary hypertension and healthy controls. To further explore the possible mechanism of hematopoietic stem cell differentiation between patients with pulmonary hypertension and healthy controls. |
